FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden

Estimated average burden hours per response: 0.5

			OI	Section 30(n) of the investment Company At	COL IS	940					
	ddress of Reportin	•	2. Date of I Requiring S (Month/Day 02/05/20	Statement y/Year)	3. Issuer Name and Ticker MELA SCIENCES			MELA]				
(Last) (First) (Middle) C/O 20 GENESIS CLOSE			-		Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				5. If Amendment, Date of Original Filed (Month/Day/Year)			
ANSBACH 1344	ER HOUSE, SI	ECOND FLOOR	_		Officer (give title below)		Other (speci below)	6.		able Line)	Group Filing (Check One Reporting Person	
(Street) GRAND CAYMAN	E9	KY1-1108							X	Form filed by Reporting Per	fore than One	
(City)	(State)	(Zip)										
			Table I -	Non-Deri	vative Securities Benef	iciall	y Owned					
1. Title of Security (Instr. 4)					Beneficially Owned (Instr. 4) Form: Di		3. Ownership Form: Direct or Indirect (I) (Instr. 5)			re of Indirect Beneficial Ownership i)		
					tive Securities Benefici rrants, options, conver)				
1. Title of Derivative Security (Instr. 4)		2. Date Exerc Expiration Day/ (Month/Day/	ate	3. Title and Amount of Secur Derivative Security (Instr. 4)	Conversion Ownership B or Exercise Form: (I		6. Nature of Indirect Beneficial Ownership (Instr. 5)					
			Date Exercisable	Expiration Date	Title		ount or ber of res	Price of Derivati Security	ve	Direct (D) or Indirect (I) (Instr. 5)		
Series A Cor per share	vertible Prefer	red Stock, \$0.10	02/05/2014	(7)	Common Stock, \$0.001 par value per share	4,76	51,905(1)(2)(3)	0.84	ļ	D ⁽⁴⁾		
Series A Cor per share	vertible Prefer	red Stock, \$0.10	02/05/2014	(7)	Common Stock, \$0.001 par value per share	4,76	61,905 ⁽¹⁾⁽²⁾⁽³⁾	0.84	ļ	I	Footnote ⁽⁶⁾	
Common Sto	ock Warrant		02/05/2014	02/05/2019	Common Stock, \$0.001 par value per share	4,32	24,324 ⁽¹⁾⁽²⁾⁽³⁾	0.74		D ⁽⁵⁾		
Common Sto	ock Warrant		02/05/2014	02/05/2019	Common Stock, \$0.001	4,32	24,324(1)(2)(3)	0.74		I	Footnote ⁽⁶⁾	

par value per share

Broadfin Hea	althcare Maste	r Fund Ltd
(Last)	(First)	(Middle)
C/O 20 GENES	IS CLOSE	
ANSBACHER	HOUSE, SECON	D FLOOR, 1344
(Street)		
GRAND	E9	KY1-1108
CAYMAN		
(City)	(State)	(Zip)
1. Name and Addre	ss of Reporting Pers	on*
Broadfin Cap	oital, LLC	
(Last)	(First)	(Middle)
,	NUE, 9TH FLOO	, ,
(Street)		
NEW YORK	NY	10017
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*

Name and Address of Reporting Person* KOTLER KEVIN								
(Last) (First) (Middle) C/O BROADFIN CAPITAL, LLC 237 PARK AVENUE, SUITE 900								
(Street) NEW YORK	NY	10017						
(City)	(State)	(Zip)						

Explanation of Responses:

- 1. On February 5, 2014, pursuant to the terms of a securities purchase agreement, dated as of January 31, 2014, Broadfin Capital, LLC was sold (i) 4,000 shares of Series A Convertible Preferred Stock, which may be converted to 4,761,901 shares of common stock of the Issuer, and (ii) a Warrant, which may be exercised for 4,324,324 shares of common stock of the Issuer. The Series A Convertible Preferred Stock and the Warrant are held in the account of Broadfin Healthcare Master Fund. Ltd.
- 2. In connection with this securities purchase agreement, Broadfin Capital, LLC shall not have the right to convert any portion of the Series A Convertible Preferred Stock or exercise the Warrant to purchase shares of common stock, to the extent that, after giving effect to the conversion or exercise, Broadfin Capital, LLC (directly or indirectly) would beneficially own in excess of 9.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock or the exercise of the Warrant held by Broadfin Capital, LLC.
- 3. In connection with Broadfin Capital, LLC's investment in the securities pursuant to the securities purchase agreement described above, Broadfin Capital, LLC has been granted the right to designate one director to the Board of Directors of the Issuer, so long as Broadfin Capital, LLC retains 30% of their investment in the Series A Preferred Stock or holds any warrants.
- 4. The Series A Convertible Preferred Stock are held in the account of Broadfin Healthcare Master Fund, Ltd.
- 5. The Warrant is held in the account of Broadfin Healthcare Master Fund, Ltd.
- 6. The securities are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
- 7 None

BROADFIN HEALTHCARE
MASTER FUND, LTD. By: /s/ 03/04/2014
Kevin Kotler, Director
BROADFIN CAPITAL, LLC
By: /s/ Kevin Kotler, Managing 03/04/2014
Member
/s/ Kevin Kotler 03/04/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.